Skip to main content

Early value dossiers for medical technologies

The essential tool to understand the value proposition for your product and position it well with reimbursement/HTA stakeholders

Learn more
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

First health apps are expected to enter reimbursement in Belgium by the end of January 2025

In December 2024, MTRC reported that the first health app, CardioCare@Home by Byteflies, appeared at Level 3+ of the mHealthBelgium validation pyramid, signifying regular reimbursement. However, the app is currently listed at Level 2.

mHealthBelgium clarified to MTRC that the December 2024 listing was part of a visual test to illustrate how an app would appear at Level 3 on their website. As of now, no health apps are officially listed at Level 3, which signifies eligibility for reimbursement.

mHealthBelgium expects the first health apps to reach Level 3 by the end of January 2025, particularly within the care pathway for "Remote monitoring and therapeutic guidance in chronic heart failure."

See the full details here and here.

This news is just one of about 300 market access news collected by our team in the premium subscription service Market Access Monitor every week from more than 80 organizations. Access our paid service to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). Access is organized as an online Database and email alert formats. Contact us to get a free, three-month, no-obligation trial.